Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Meth-OD: A Phase 2a Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

NCT04715230 is registered in ClinicalTrials.gov with InterveXion Therapeutics, LLC as lead sponsor.

NCT NCT04715230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04715230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Meth-OD: A Phase 2a Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
Lead sponsor
InterveXion Therapeutics, LLC
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2021
Completion date
November 14, 2022
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine intoxication (disorder)